APA (7th ed.) Citation

Y, S., T, Y., D, N., H, S., T, K., Y, M., . . . T, N. (2012). Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: Immunologic evidence and potential for improving overall survival. Clinical cancer research : an official journal of the American Association for Cancer Research, 18(13), 3686. https://doi.org/10.1158/1078-0432.CCR-11-3044

Chicago Style (17th ed.) Citation

Y, Sawada, et al. "Phase I Trial of a Glypican-3-derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 18, no. 13 (2012): 3686. https://doi.org/10.1158/1078-0432.CCR-11-3044.

MLA (9th ed.) Citation

Y, Sawada, et al. "Phase I Trial of a Glypican-3-derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 18, no. 13, 2012, p. 3686, https://doi.org/10.1158/1078-0432.CCR-11-3044.